Concord Biotech Stock Screener | Share Price & Fundamental Analysis
CONCORDBIO
Pharmaceuticals
Screen Concord Biotech share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1337.70
▲
26.20 (2.00%)
Share Price BSE
₹1338.60
▲
28.85 (2.20%)
Market Cap
₹14,014.39 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
7.65
EPS (TTM)
₹35.52
Dividend Yield
0.65%
Debt to Equity
-
52W High
₹2345.60
52W Low
₹1311.50
Operating Margin
44.00%
Profit Margin
31.89%
Revenue (TTM)
₹439.00
EBITDA
₹198.00
Net Income
₹140.00
Total Assets
₹2,034.00
Total Equity
₹1,813.00
Concord Biotech Share Price History - Stock Screener Chart
Screen CONCORDBIO historical share price movements with interactive charts. Analyze price trends and patterns.
Concord Biotech Company Profile - Fundamental Screener
Screen Concord Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CONCORDBIO shares.
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
SUDHIR JAIRAM VAID
ISIN
INE338H01029
Website
https://www.concordbiotech.com
Concord Biotech Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen CONCORDBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 2,034 | 1,701 | 1,514 | 1,313 | 941 |
| Current Assets | 1,135 | 896 | 728 | 633 | 539 |
| Fixed Assets | 795 | 575 | 593 | 573 | 240 |
| Liabilities | |||||
| Total Liabilities | 2,034 | 1,701 | 1,514 | 1,313 | 941 |
| Current Liabilities | 38 | 32 | 32 | 54 | 55 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 1,813 | 1,527 | 1,290 | 1,103 | 770 |
| Share Capital | 11 | 11 | 11 | 10 | 10 |
| Reserves & Surplus | 1,802 | 1,516 | 1,280 | 1,094 | 761 |
Screen CONCORDBIO income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 439 | 219 | 263 | 330 | 228 | 320 | 261 | 285 | 208 | 271 | 252 | 195 | 165 | 250 |
| Expenses | 241 | 143 | 159 | 187 | 135 | 177 | 146 | 146 | 123 | 147 | 135 | 116 | 122 | 131 |
| EBITDA | 198 | 77 | 104 | 143 | 93 | 144 | 115 | 139 | 85 | 124 | 117 | 79 | 44 | 119 |
| Operating Profit % | 44.00% | 30.00% | 36.00% | 41.00% | 38.00% | 43.00% | 40.00% | 47.00% | 37.00% | 44.00% | 44.00% | 36.00% | 24.00% | 46.00% |
| Depreciation | 15 | 18 | 18 | 14 | 13 | 13 | 13 | 14 | 13 | 13 | 14 | 14 | 13 | 14 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 184 | 59 | 86 | 129 | 80 | 130 | 101 | 124 | 71 | 110 | 103 | 64 | 30 | 105 |
| Tax | 43 | 15 | 23 | 34 | 20 | 35 | 25 | 32 | 17 | 29 | 26 | 15 | 8 | 27 |
| Net Profit | 140 | 44 | 63 | 95 | 60 | 96 | 76 | 92 | 55 | 81 | 78 | 49 | 22 | 77 |
| EPS | 13.42 | 4.21 | 6.03 | 9.08 | 5.70 | 9.15 | 7.26 | 8.75 | 5.21 | 7.74 | 7.41 | 4.71 | 2.10 | 7.40 |
Concord Biotech Cash Flow Screener - Liquidity Fundamentals
Screen CONCORDBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 245 | 266 | 246 | 208 | 167 | 155 |
| Investing Activities | -160 | -155 | -158 | -112 | -195 | -114 |
| Financing Activities | -99 | -99 | -85 | -100 | 31 | -43 |
| Net Cash Flow | -14 | 12 | 3 | -5 | 3 | -1 |
Screen CONCORDBIO shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Aug |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FII Holding | 9.35% | 9.11% | 8.03% | 6.48% | 7.11% | 8.10% | 8.33% | 0.00% |
| DII Holding | 9.16% | 8.87% | 9.55% | 8.46% | 10.40% | 9.89% | 9.66% | 4.89% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.94% | 7.43% | 7.77% | 7.08% | 7.64% | 7.33% | 7.33% | 13.33% |
| Other Holding | 30.47% | 30.51% | 30.56% | 33.90% | 30.76% | 30.61% | 30.59% | 37.69% |
| Shareholder Count | 81,219 | 82,045 | 82,650 | 83,296 | 80,737 | 84,298 | 82,004 | 377,572 |
Concord Biotech Dividend Screener - Share Yield Analysis
Screen CONCORDBIO dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹10.70 | 0.80% |
| 2024-March | ₹8.75 | 0.52% |
| 2023-March | ₹6.83 | 0.45% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Concord Biotech Index Membership - Market Screener Classification
Screen CONCORDBIO by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Concord Biotech Market Events Screener - Corporate Actions
Screen CONCORDBIO market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -2.31% | ||
| Dividend | ₹ 10.70 /share | 3.39% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 4.87% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -6.13% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 6.76% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -0.32% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 2.08% |
| 2024-06-29 | 2024-06-29 | Annual General Meeting | NA | 6.09% |
| 2024-06-21 | 2024-06-22 | Dividend | ₹ 8.75 /share | 6.79% |
Concord Biotech Competitors Screener - Peer Comparison
Screen CONCORDBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.37 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,599 | 67.76 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,528 | 60.85 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.30 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,245 | 18.24 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,065 | 22.10 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,458 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,748 | 50.34 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,737 | 20.25 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,737 | 27.11 | 13,458 | 3.70% | 2,216 | 38.49 |
Concord Biotech Company Announcements - News Screener
Screen CONCORDBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2025-12-18 | Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations 2015 | View |
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-18 | Board Meeting Outcome for Appointment Of CFO And KMP | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Cessation | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-19 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-13 | Financial Results For The Period Ended 30 September 2025 | View |
| 2025-11-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On 13/11/2025 | View |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-08 | Board Meeting Intimation for Financial Results | View |
| 2025-10-08 | Successful Completion Of NAFDAC Inspection | View |
| 2025-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-25 | Closure of Trading Window | View |
| 2025-09-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-09-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |